Isomorphic Labs in talks to raise $5B at about $50B valuation

The scale of the round, not the science, is the story here: a private AI drug-discovery company seeking one of the year's largest private raises signals that capital is still concentrating around a handful of platform bets rather than spreading across the sector. Alphabet's backing gives the valuation a credibility anchor that most AI-biotech peers lack, which matters for how comparable private names get marked. The absence of a timeline or investor list is the open question — who funds a round this size, and on what terms, will say more about appetite for long-horizon discovery risk than the headline number does.